Swedish Orphan Biovitrum AB · OMXSTO:SOBI
Swedish Orphan Biovitrum AB — Q4 2014 Earnings Presentation
27 slides from Swedish Orphan Biovitrum AB's earnings presentation, Feb 19, 2015
Slide 1: Q4 and FY Results 2014
Q4 and FY Results 2014 Geoffrey McDonough │ CEO Alan Raffensperger │ COO Mats-Olof Wallin │ CFO Stockholm | 19 February 2015
Slide 2: Highlights Q4 2014
Highlights Q4 2014 Business • Received positive CHMP opinion for Xiapex® for the treatment of Peyronie's disease • Exercised opt-in right for Elocta™ • Marketing Authorisation Application for Elocta filed and validated for review by EMA • Orfadin® approved in Japan Significant events after the repor
Slide 3: Highlights Q4 2014
Highlights Q4 2014 800 • Total revenues: SEK 705 M (611) • An increase of 15% Total Revenue 700 • In constant exchange rates revenues increased 9 % 600 • Product revenues: SEK 575 M (448) 500 • An increase of 28% 400 Product Revenue • ReFacto revenues: SEK 130 (163) • A decrease of 20% 300 200 ReFac
Slide 4: Highlights Full Year 2014
Highlights Full Year 2014 3,000 • Total revenues: SEK 2,607 M (2,177) 2,607 • An increase of 20% 2,500 • At constant exchange rates 15% 2,177 2,000 • Product revenues: SEK 1,989 M (1,558) 1,548 • An increase of 28% 1,500 1,284 1,000 • Gross margin 59 (59) 500 307 211 211 0 • EBITA: SEK -43 M (211) -
Slide 5: Full Year Revenue by Business Line
Full Year Revenue by Business Line Early Stage Total revenue Development Programmes FY 2014 SEK 2,607 M Haemophilia SEK 31 M USD 5 M +15%* Genetics & Inflammation SEK 609 M Metabolism +3%* +40%* SEK 666 M FY 2013 USD 89 M USD 97 M SEK 2,177 M Partner Products SEK 682 M +21%* USD 99 M ReFacto AF® SEK
Slide 6: Divided into Four Regional Platforms
Divided into Four Regional Platforms EMENAR Haemophilia SCPP North America ReFacto • Elocta (& Alprolix) • Orfadin, Kineret, • Orfadin, Kineret®, • ReFacto Kepivance® Kepivance manufacturing • ReFacto Royalty • Partner Product portfolio Fuel to build a global A leading specialty and A robust platfor
Slide 7: ReFacto AF
ReFacto AF Sales (SEK M): ReFacto • Q4 revenue for manufacturing and 250 700 royalty SEK 130 M (163) • FY revenue SEK 618 M (619) 600 200 • 2013 included validation batches of SEK 66 M 500 150 400 • Q4 manufacturing revenue SEK 99 M (146) 300 100 200 50 • Q4 royalty revenue SEK 31 M (16) 100 0 0 Q1
Slide 8: Commercial Results Q4 & FY 2014
Commercial Results Q4 & FY 2014 Alan Raffensperger │ COO Stockholm | 19 February 2015
Slide 9: Kineret
Kineret Sales (SEK M): Kineret • Revenue SEK 163 M (164) 200 700 • FY revenue 609 (562), an increase of 8% 180 600 160 500 • US sales in Q4 2013 were positively 140 impacted by a change of wholesaler. 120 400 100 80 300 • Growth driven primarily by price in 60 200 the US and volume in Europe 40 100
Slide 10: Orfadin
Orfadin Sales (SEK M): Orfadin • Revenue SEK 169 M (91) 180 600 • FY revenue SEK 548 M (366), an increase of 50% • Includes SEK 4.8 M milestone payment from 160 Astellas 500 140 120 400 • Continued impact of direct sales model in North America 100 300 80 • Volume growth particularly in Middle 60 200
Slide 11: Partner Products
Partner Products Sales (SEK M): Partner Products • Revenue SEK 198 M (173) 250 800 • FY revenue SEK 682 M (546), an increase of 25% 700 200 600 • Increase was driven by new partnerships and by growth of the 500 150 base portfolio 400 100 300 • 7 product launches in 21 countries 200 50 100 • Xiapex a
Slide 12: Partner Products Annual Growth Trend
Partner Products Annual Growth Trend • Significant turnaround over past MSEK Revenue three years 800 CAGR 700 682 • Driven by a combination of portfolio 27% 600 546 growth and new deals 500 423 400 300 200 100 0 2012 2013 2014 12
Slide 13: Haemophilia
Haemophilia Sales (SEK M): Haemophilia • Q4 2014 revenue of SEK 12 M (0) 14 12 • FY was SEK 31 M (0) 10 8 • SEK 11 M relates to a milestone 6 revenue for the BLA approval of Alprolix® in Q1 2014 4 2 0 Q1 Q2 Q3 Q4 2014 Milestone Alprolix Alprolix Eloctate 13
Slide 14: Expected Long Acting FVIII EU timeline
Expected Long Acting FVIII EU timeline EU MAA filing Sobi opt-in Possible EMA approval Elocta launch in EU (Sobi territory) Sobi 2014 2015 2016 2017 2018 Competitors First potential long-acting FVIII competitors* * Based on publically announced data 14
Slide 15: Haemophilia A in Sobi Territory
Haemophilia A in Sobi Territory Size of Market (M) in Sobi Territories* USD 3.3 B SEK 23 B *Source: MRB, 2011, includes all patients (mild, moderate, severe) 15
Slide 16: Sobi Launch Team on Track
Sobi Launch Team on Track Headcount • Preparation has been ongoing for 120 Anticipated EU Approval two years Elocta™ Q4 2015 100 • On track to reach launch readiness in 80 2015 with fully dedicated organisation 60 • Sequential build of Market Access, 40 Medical Affairs, and Commercial teams 20 0 H2
Slide 17: Financial Results Q4 & FY 2014
Financial Results Q4 & FY 2014 Mats-Olof Wallin │ CFO Stockholm | 19 February 2015
Slide 18: Profit and Loss Statement
Profit and Loss Statement Amounts in SEK M Q4-14 Q4-13 FY 2014 FY 2013 Total revenues 705 611 2,607 2,177 Gross profit 427 358 1,548 1,284 Gross Margin 60% 59% 59% 59% Sales and Administration -214 -192 -750 -621 Research and development -149 -102 -501 -456 Other operating revenues/expenses -25 2 -3
Slide 19: Balance Sheet
Balance Sheet Amounts in SEK M Dec 2014 Dec 2013 ASSETS Intangible 4,248 4,637 Tangible and financial 188 152 Total non-current assets 4,436 4,789 Inventories 764 726 Accounts receivable 480 415 Other Receivable 172 145 Cash and equivalent 519 445 Total current assets 1,935 1,730 Total Asset 6,371 6
Slide 20: Net Debt
Net Debt 500 50% • End of quarter cash: SEK 519 M 400 40% • Net debt SEK 298 M 300 30% • Significant payments to partner in Q4 SEK M • XTEN payment Q4, USD 7 M 200 20% • Elocta opt-in Q4, USD 10 M 100 10% 0 0% Q1-12 Q2-12 Q3-12 Q4-12 Q1-13 Q2-13 Q3-13 Q4-13 Q1-14 Q2-14 Q3-14 Q4-14 Net debt Net debt
Slide 21: Royalty Mechanism Revenues Eloctate/Elocta Programme
Royalty Mechanism Revenues Eloctate/Elocta Programme Base cross royalty rates between Sobi and Biogen Idec are set to 12% PnL impact at Sobi first • Sobi earns 12% royalty on Biogen Idec sales • Biogen Idec earns 12% royalty on Sobi sales commercial sales: • One-time credit and Presently royalty boo
Slide 22: Summary and Outlook
Summary and Outlook Geoffrey McDonough │ CEO Stockholm | 19 February 2015
Slide 23: Outlook 2014
Outlook 2014 The company exceeded its revenue outlook for 2014, which estimated the total revenues for the full year to be in the range of SEK 2,300 to 2,500 M. The gross margin met the range of 58-60 per cent at 59 per cent. The outlook was first published in the 2013 Q4 report on 20 February 2014.
Slide 24: Outlook 2015
Outlook 2015 Revenues Sobi expects total revenues for the full year to be in the range of SEK 2,800 to 3,000 M Gross Margin Gross margin is expected be in the range of 58-60 percent. Operating Costs Operating costs are projected to increase as the company continues to prepare for the planned launch
Slide 25: Building Our Future
Building Our Future Continued focus on our business and capabilities within rare diseases 1. Diverse, growing, and profitable base business in Europe and North America focused on rare diseases 2. Launching first-to-market long- acting haemophilia factors in Sobi territories – providing forward cash
Slide 26: Building a Leading Rare Disease Company
Building a Leading Rare Disease Company EBITA Short-term Medium- Long-term Development Programmes term Haemophilia Genetics & Inflammation Metabolism Partner Products Early Programmes ReFacto AF® Haemophilia Haemophilia royalties Genetics & Metabolism Inflammation Partner Products ReFacto 2012 - 2013
Slide 27: Strategic Priorities
Strategic Priorities 1. Near-term focus on growth in our base business, with sustainable positive cash flow from operations. 2. Medium-term investments to ensure successful commercialisation of our haemophilia programmes. 3. Long-term growth will come organically and through acquisitions. 27
Swedish Orphan Biovitrum (Sobi) — Q4 2014 Earnings Presentation on 6ix